TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03404674

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CssBA
Description: Recombinant enterotoxigenic Escherichia coli (ETEC) surface antigen 6 containing modified structural subunits A and B

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CssBA
Description: Recombinant enterotoxigenic Escherichia coli (ETEC) surface antigen 6 containing modified structural subunits A and B

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CssBA
Description: Recombinant enterotoxigenic Escherichia coli (ETEC) surface antigen 6 containing modified structural subunits A and B

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CssBA
Description: Recombinant enterotoxigenic Escherichia coli (ETEC) surface antigen 6 containing modified structural subunits A and B

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CssBA
Description: Recombinant enterotoxigenic Escherichia coli (ETEC) surface antigen 6 containing modified structural subunits A and B

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: dmLT
Description: Escherichia coli double mutant heat-labile toxin with mutations at amino acids 192 and 211

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: dmLT
Description: Escherichia coli double mutant heat-labile toxin with mutations at amino acids 192 and 211
Study: NCT02877277

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: Oral intake of vitamin C tablet (500 mg) daily for 56 days
Study: NCT03404674

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: dmLT
Description: Escherichia coli double mutant heat-labile toxin with mutations at amino acids 192 and 211

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: dmLT
Description: Escherichia coli double mutant heat-labile toxin with mutations at amino acids 192 and 211

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: dmLT
Description: Escherichia coli double mutant heat-labile toxin with mutations at amino acids 192 and 211
Study: NCT01594255

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sotrastaurin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sotrastaurin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo to sotrastaurin
Study: NCT00070642

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Chemotherapy in three-week cycles until disease progression:~dacarbazine 850mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPG 7909 Injection
Description: CPG 7909 Injection administered subcutaneously at a dose of 10 mg weekly.
Study: NCT01594255

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Avelox
Study: NCT00391560

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: perifosine
Description: Identical intervention in both arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: perifosine
Description: Identical intervention in both arms.
Study: NCT00916643

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HELP Secura (apheresis treatment)
Description: Process is described in Arm (above).
Study: NCT03203200

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ZETRA cognitive behavioral structural
Description: ZETRA cognitive behavioral structural
Study: NCT03168022

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A
Description: 1 x TNX-102 SL 2.8 mg yellow tablet (commercial manufacturer) to be held under the tongue until dissolved.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B
Description: 1 x TNX-102 SL 2.8 mg white tablet (original manufacturer) to be held under the tongue until dissolved.
Study: NCT02216500

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketogenic Therapy
Description: Ketogenic Therapy is based on a ratio of fat: protein+carbohydrate in which protein intake is adequate, fat intake is high, and carbohydrate intake is minimal.
Study: NCT03548727

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET/CT Imaging
Description: PET/CT Imaging of tumor hypoxia and proliferation

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET/CT Imaging
Description: PET/CT Imaging of tumor hypoxia and proliferation
Study: NCT02477410

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hydrolysed porcine protein from blood
Description: Effects of hydrolysed porcine proteins on muscle protein synthesis and appetite

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hydrolysed porcine protein from muscle
Description: Effects of hydrolysed porcine proteins on muscle protein synthesis and appetite

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hydrolysed whey protein
Description: Effects of hydrolysed porcine proteins on muscle protein synthesis and appetite
Study: NCT06550739

Intervention type: OTHER
Intervention: Randomization
Description: Randomly divide the data into a training set and a validation set in a 7:3 ratio

Intervention type: OTHER
Intervention: Randomization
Description: Randomly divide the data into a training set and a validation set in a 7:3 ratio
Study: NCT02702570

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: CASA
Description: Each participant serves as his/her own control. Measures administered before and after the behavioral intervention.
Study: NCT02455895

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: iLid Cleanser
Description: Application of iLid Cleanser to reduce bacterial load on the lid and lash margins

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: iLid Cleanser
Description: Application of iLid Cleanser to reduce bacterial load on the lid and lash margins
Study: NCT00711035

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivirus Specific CTLs for EBV, CMV and Adenovirus Infection
Description: Follow-up Assessments: The timing of follow-up visits is based on the date of CTL infusion. If a patient has multiple CTL doses the schedule resets again at the beginning so follow up relates to the last CTL dose.~Follow up will occur at 7 days, 14 days, 21 days, 28 days, 42 days, 90 days, 180 days, and 365 days post enrollment.
Study: NCT02535689

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tofacitinib
Description: Oral administration of tofacitinib, 5 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tofacitinib
Description: Oral administration of tofacitinib, 5 mg
Study: NCT02877277

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral intake of placebo tablet daily for 56 days
Study: NCT01119989

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Fructose+maltodextrin placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: amino-acid + fructose
Study: NCT03921931

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: White light stimulation
Description: Stimulation of the retina with white light

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: White light stimulation
Description: Stimulation of the retina with white light

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: White light stimulation
Description: Stimulation of the retina with white light
Study: NCT01948739

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MAHI EXO-II exoskeleton augmented with BMI system
Description: In this longitudinal study, adult subjects with hemiparesis due to acute or chronic stroke will receive robotic-assisted training through an EEG-based BMI control of robotic exoskeleton to study the changes in upper extremity motor function, cortical plasticity (using the EEG and fMRI). The training will be provided 3x/week for 12 sessions over one-month period.
Study: NCT01160068

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin Tablets 1000 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucophage
Description: Glucophage 1000 mg tablets of Bristol-Myers Squibb
Study: NCT01168635

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Spirometry 360 program - Virtually-delivered spirometry quality improvement program
Description: The Spirometry 360 program includes:~1. Spirometry Fundamentals™: A basic guide to lung function testing, a computer-based training program that teaches primary care providers how to coach patients to produce high-quality spirometry tests and accurately interpret spirometric data;~2. Spirometry Learning Lab: Case-based teaching of spirometry in practice guides test administrators and interpreters through clinical examples in an interactive virtual classroom setting. These sessions are led by expert clinical faculty and are archived for future reference and review;~3. Spirometry Feedback: Tailored analysis of providers' spirometry testing sessions offers monthly individualized feedback reports by clinical experts on spirometry tests performed in the clinic.
Study: NCT00433056

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: STI
Description: CD4 guided treatment interruption

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: stable HAART
Description: continuous therapy
Study: NCT00070642

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPG 7909 Injection
Description: CPG 7909 Injection administered subcutaneously at a dose of 40 mg weekly.
Study: NCT02311439

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRINOX + CRT
Description: Induction 4 times chemotherapy, FOLFIRINOX regimen, consisted of Oxaliplatin at a dose of 85 mg/m2 D1, 2-hour I.V + Irinotecan 180 mg/m2 D1 90-minute I.V. + Leucovorin 200 mg/m2 2- hour I.V, D1,2 + (5-FU) dosed at 400 mg/m2, administered as an intravenous bolus on day 1 and day 2, followed by a continuous intravenous infusion of 600 /m2 over a 20- hours period on day 1 and day 2. Treatment will be administered every 2 weeks. G-CSF will be administrated according to the need.~In non-progressed cases, will be followed by consolidation concurrent radiotherapy with capecitabine 625 mg/m2 BID.~Radiotherapy :~A fractionated dose of 50.4Gy /28 fractions/15 MeV photon energy generated by Dual-energetic Linear Accelerator.
Study: NCT03001258

Intervention type: OTHER
Intervention: Presbyopia screening training
Description: The training module and the protocol were designed in a way that a layman with limited education could be trained for screening and could sell reading glasses without any hassle, accurately and responsibly. Training module included the general anatomy of eye, common vision problems, aetiologies, determination of proper acuity of vision, sales techniques of the reading glass, marketing of products and services, and management of inventory and referrals. All the providers who participated in the current study, had no prior experience/training of screening presbyopia before the intervention. Each of the intervention arm used letter acuity chart i.e. Snellen chart as it commonly used for as a test of visual acuity

Intervention type: OTHER
Intervention: Presbyopia screening training
Description: The training module and the protocol were designed in a way that a layman with limited education could be trained for screening and could sell reading glasses without any hassle, accurately and responsibly. Training module included the general anatomy of eye, common vision problems, aetiologies, determination of proper acuity of vision, sales techniques of the reading glass, marketing of products and services, and management of inventory and referrals. All the providers who participated in the current study, had no prior experience/training of screening presbyopia before the intervention. Each of the intervention arm used letter acuity chart i.e. Snellen chart as it commonly used for as a test of visual acuity

Intervention type: OTHER
Intervention: Presbyopia screening training
Description: The training module and the protocol were designed in a way that a layman with limited education could be trained for screening and could sell reading glasses without any hassle, accurately and responsibly. Training module included the general anatomy of eye, common vision problems, aetiologies, determination of proper acuity of vision, sales techniques of the reading glass, marketing of products and services, and management of inventory and referrals. All the providers who participated in the current study, had no prior experience/training of screening presbyopia before the intervention. Each of the intervention arm used letter acuity chart i.e. Snellen chart as it commonly used for as a test of visual acuity
Study: NCT03087968

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-4997
Description: Experimental drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Control drug that is also administered with the Experimental drug, GS-4997. This drug is used in both arms.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisolone
Description: Control drug that is also administered with the Experimental drug, GS-4997. This drug is used in both arms.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HepQuant SHUNT Test
Description: The HepQuant SHUNT Liver Diagnostic Kit is intended for use in the quantitative detection of 13C-cholate and d4-cholate in blood serum, collected after the intravenous administration of 13C-cholate and the oral ingestion of d4-cholate. The device is indicated to assess the severity of liver disease.~For use by health care professionals. Administer the test under a physician's supervision. The HepQuant Analytical Testing Laboratory must analyze the serum samples.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: HepQuant SHUNT Test
Description: The HepQuant SHUNT Liver Diagnostic Kit is intended for use in the quantitative detection of 13C-cholate and d4-cholate in blood serum, collected after the intravenous administration of 13C-cholate and the oral ingestion of d4-cholate. The device is indicated to assess the severity of liver disease.~For use by health care professionals. Administer the test under a physician's supervision. The HepQuant Analytical Testing Laboratory must analyze the serum samples.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04078828

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic floor Reconstruction
Description: Pelvic floor Reconstruction after laparoscopic anterior resection and double-stapling technique anastomosis were finished.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic floor Reconstruction
Description: Pelvic floor Reconstruction after laparoscopic anterior resection and double-stapling technique anastomosis were finished.
Study: NCT03461900

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Minifluid challenge
Description: Pragmatic optimization fluid management protocol based on Mini-Fluid Challenge (MFC) in treating an acute circulatory failure. MFC consist of an infusion of 100 ml of colloid solution (4% human serum albumin) during 1 minute via a separate venous line. Before and after each MFC and depending on the hemodynamic device used, the attending physician will perform a first set of hemodynamic measurements, including cardiac index (CI) or cardiac output (CO); stroke volume (SV), indexed stroke volume (iSV) or velocity time index (VTI). If the variation in measurement is superior to 10%, the attending physician will infuse 400 ml of buffered crystalloid solution or saline solution. After an infusion of 500 ml, fluid responsiveness will be evaluated with CI or CO measurement. For non-responders, fluid challenge must be stopped and other therapeutics should be considered. For responder, another MFC should be consider if hemodynamic status is not stabilized.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual practice
Description: Patients included in control group will be managed according to the last surviving sepsis recommendations edited in 2017.
Study: NCT03741036

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Autogenous bone graft as space filling in immidiate implant placment
Description: * The selected patients will be informed of the nature of the research work and informed consent will be obtained (immediate implant placement grafting with autogenous bone graft)~* Patients will be subjected to CBCT (diagnostic for upper arch).~* Local anesthesia will be given to the patient.~* Scrubbing and draping of the patient will be carried out in a standard fashion for intra oral procedures.~* The procedure will be carried out flapless.~* In the study group: Atraumatic extraction~* The extraction socket will be evaluated for absence of any fenestration or granulation tissues

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Deprotinized bovien as space filling in immidate implant placement
Description: * The selected patients will be informed of the nature of the research work and informed consent will be obtained (immediate implant placement grafting with deprotinized bovien material)~* Patients will be subjected to CBCT (diagnostic for upper arch).~* Local anesthesia will be given to the patient.~* Scrubbing and draping of the patient will be carried out in a standard fashion for intra oral procedures.~* The procedure will be carried out flapless.~* In the study group: Atraumatic extraction~* The extraction socket will be evaluated for absence of any fenestration or granulation tissues

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nano-hydroxiapatite alloplast in immidiate implant placement
Description: * The selected patients will be informed of the nature of the research work and informed consent will be obtained (immediate implant placement grafting with nano-hydroxiapatite alloplast material )~* Patients will be subjected to CBCT (diagnostic for upper arch).~* Local anesthesia will be given to the patient.~* Scrubbing and draping of the patient will be carried out in a standard fashion for intra oral procedures.~* The procedure will be carried out flapless.~* In the study group: Atraumatic extraction~* The extraction socket will be evaluated for absence of any fenestration or granulation tissues
Study: NCT03096652

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Approach for cancer resection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Approach for cancer resection
Study: NCT01734564

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hiltonol and autologous dendritic cells
Description: Hiltonol and autologous dendritic cells

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hiltonol, dendritic cells and radiation
Description: Hiltonol, autologous dendritic cells and radiation therapy. Radiation therapy will pursue an abscopal effect.
Study: NCT03675490

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ABLE - exercise with interactive technology
Description: Multicomponent exercise with interactive technology - consists of wearable sensors and a screen displaying interaction. When the person does the exercises it produces an arts-based response on the screen (e.g., digital painting).,
Study: NCT02476968

Intervention type: DRUG
Group type: OTHER
Intervention: Olaparib
Description: Olaparib Capsule - 50 mg. Olaparib capsules will be packed in high-density polyethylene (HDPE) bottles with child-resistant closures. Each bottle will contain 120 capsules and 4 bottles will be dispensed for a 4 weekly visit, with a 2 day overage.~Patients will be administered olaparib capsules orally at a dose of 400 mg twice daily.~Eight 50 mg olaparib capsules should be taken at the same time each day approximately 12 hours apart with approximately 240 mL of water.
Study: NCT03938194

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Aquablation
Description: a novel minimally invasive water ablation therapy combining image guidance and robotics for the targeted and heat-free removal of prostate tissue
Study: NCT01972269

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine-fentanyl
Description: 0.125% bupivacaine-fentanyl 5mcg/mL

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine-fentanyl
Description: 0.125% bupivacaine-fentanyl 5mcg/mL

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine-fentanyl
Description: 0.125% bupivacaine-fentanyl 5mcg/mL

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine-fentanyl
Description: 0.125% bupivacaine-fentanyl 5mcg/mL

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine-fentanyl
Description: 0.125% bupivacaine-fentanyl 5mcg/mL

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine-fentanyl
Description: 0.125% bupivacaine-fentanyl 5mcg/mL

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine-fentanyl
Description: 0.125% bupivacaine-fentanyl 5mcg/mL

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine-fentanyl
Description: 0.125% bupivacaine-fentanyl 5mcg/mL

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine-fentanyl
Description: 0.125% bupivacaine-fentanyl 5mcg/mL
Study: NCT03815201

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Group 1
Description: placebo, an energy-matched mixture, during the first 1/2 hour post-training
Study: NCT02406599

Intervention type: DEVICE
Group type: OTHER
Intervention: Margin Probe
Description: The surgeon will use the MarginProbe System to identify cancerous tissue at the margins (≤ 1mm) of the main ex-vivo lumpectomy specimen following primary excision

Intervention type: OTHER
Group type: OTHER
Intervention: Control: Additional inspection
Description: The surgeon will perform additional inspection and assessment of the margins of the main ex-vivo lumpectomy specimen following primary excision
Study: NCT01229592

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethanol
Description: Every three day lock using Ethanol(70%)in all the lumen(1ml/per lumen) of the Catheter

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparine
Description: Every three day lock using Heparin(Fibrilin TM) 3ml in all the lumen of the Catheter
Study: NCT04418752

Intervention type: OTHER
Group type: OTHER
Intervention: Psychological therapy
Description: The National Institute for Health and Care Excellence (2018) specifies NET as a psychological intervention for the treatment of PTSD or prominent symptoms of PTSD in adults. NET is a short-term treatment which incorporates elements of CBT exposure therapy and testimonial therapy. In exposure therapy, clients are encouraged to repeatedly discuss traumatic experiences in detail, including emotions and sensory experiences (Schauer, Elbert, \& Neuner, 2011).Testimonial therapy involves the construction of a detailed and coherent report of the survivor's biography including an explicit description of the traumatic events (Neuner, Schauer, Roth \& Elbert, 2002, pp.5-6). Therefore, NET aims to embed the traumatic experience within the context of the person's life and the mechanisms of change are theorised to be exposure and habituation to the traumatic experience and the reconstruction of autobiographical memory.